Literature DB >> 15222117

[A case report of unresectable gastric cancer that responded to 5-FU plus paclitaxel (FT) therapy].

Takanori Matsui1, Hiroshi Kojima, Junji Kato, Takanori Uemura, Taiki Kojima, Yasunobu Fujimitsu, Kenji Tanehiro, Hitoshi Inagaki, Junichi Sakamoto.   

Abstract

We report a case of a 63-year-old man who has been treated by FT therapy (5-fluorouracil (5-FU) plus paclitaxel therapy). The regimen includes 600 mg/m2/day of 5-FU by continuous i.v. administration from day 1 to 5 and consequent administration of paclitaxel (90 mg/m2/day) on days 8, 15, and 22 for 28 days repetitively. Before the therapy was started, that occurred were obstructive jaundice, ascites, and poor performance status due to gastric cancer were observed. After percutaneous transhepatic drainage was performed, the patient was started on the above-mentioned regimen even before full recovery from the hepatic dysfunction. As the treatment proceeded, he showed good response (ascites disappeared and the size of swollen perigastric lymph node was reduced, which were confirmed as a partial response by sequential CT examination) to the therapy and his QOL and PS also improved. He has continued to receive this regimen for over 1 year and 4 months without any sign of progressive disease by CT examination. No adverse event greater than grade 1 by the NCI-CTC criteria was seen, except for alopecia (grade 2). Considering the favorable response and mild toxicity, this regimen is useful even for the patients with poor performance status and severe hepatic dysfunction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15222117

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  1 in total

1.  One-channel double stent implantation for hilar biliary obstructions.

Authors:  Guangshao Cao; Huicun Cao; Jian Liu; Yudan Wang; Zhenyu Wang
Journal:  Exp Ther Med       Date:  2013-01-23       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.